Llwytho...
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Small cell lung cancer (SCLC), which accounts for 10%–15% of lung cancer cases, is an aggressive disease characterized by rapid growth and early widespread metastasis. Although up to 80% of patients respond to first-line chemotherapy, most eventually relapse, and there are no approved agents beyond...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncologist |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
AlphaMed Press
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4978554/ https://ncbi.nlm.nih.gov/pubmed/27354668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0523 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|